Clinical trials
HER2-positive Breast Cancer clinical trials
Below are recruiting her2-positive breast cancer clinical trials, each written for real people, not researchers. We’re tracking 243 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05523947RecruitingPhase 1/Phase 2
Study drug for HER2-positive solid tumors, with dose changes
This early-stage study tests YH32367, a drug for people whose cancer is HER2-positive. It aims to find a safe dose and see whether it can shrink HER2-positive cancers that have spread or are hard to treat.
Boston, MassachusettsAges 18 years+ - NCT05461768RecruitingPhase 1
BL-M07D1 for HER2-positive or HER2-low breast cancer
This Phase 1 study tests BL-M07D1, a new investigational medicine, in people with HER2-positive or HER2-low breast cancer (and other solid tumors) that can’t be operated on or has spread. It aims to find a safe dose and learn how well the treatment may work based on HER2 levels in tumor tissue.
Fuzhou, FujianAges 18–75 - NCT05388149RecruitingPhase 2
Neratinib plus Kadcyla to treat leftover HER2 breast cancer
This trial studies whether adding neratinib to Kadcyla (T-DM1) can help eliminate “molecular residual disease,” meaning tiny traces of cancer left after surgery and standard HER2 treatment. It’s for adults with HER2-positive breast cancer who still test positive after a short course of Kadcyla, with no signs of cancer returning or spreading on scans.
Toronto, OntarioAges 18 years+ - NCT05325632RecruitingPhase 2
HER2 breast cancer vaccine plus chemo and targeted antibodies
This Phase 2 study tests a personalized immune-therapy vaccine made from your immune cells, given with weekly paclitaxel and HER2-targeted antibodies (trastuzumab and pertuzumab). It aims to improve treatment outcomes for people with HER2-positive breast cancer before standard local treatment (like surgery and radiation).
Tampa, FloridaAges 18 years+ - NCT05306041RecruitingPhase 2
Pre-surgery hormone therapy with or without PI3K inhibitor
This trial tests whether giving hormone-blocking treatment before surgery works better when combined with an added targeted drug for certain breast cancers. It may help shrink the tumor and improve outcomes for people whose tumors have specific hormone and genetic features.
Essen, North Rhine-WestphaliaAges 18 years+ - NCT05115474RecruitingPhase 2
Screening brain MRI study for stage IV breast cancer
This trial checks whether taking screening brain MRI scans in people with stage IV breast cancer helps find brain involvement earlier. It may help guide treatment decisions for those who would otherwise only get brain imaging after symptoms start.
Clearwater, FloridaAges 18 years+ - NCT05035836RecruitingPhase 2
Test drug after early HER2-positive breast cancer surgery
This trial tests zanidatamab, a type of targeted antibody treatment, in people with early-stage HER2-positive breast cancer to see how well it works and how safe it is. Because it’s a single-arm pilot study, everyone in the study gets the drug, and you’ll likely be asked to undergo standard surgery if appropriate.
Houston, TexasAges 18 years+ - NCT04886531RecruitingPhase 2
Pre-surgery neratinib plus hormone therapy with trastuzumab
This study tests whether a pre-surgery treatment plan that adds neratinib to hormone therapy and trastuzumab can shrink HER2-positive, ER-positive breast cancer before surgery. It may help patients by improving how much cancer is eliminated at the time of surgery.
Chicago, IllinoisAges 18 years+ - NCT04893109RecruitingPhase 2
Study compares two HER2 breast cancer treatments after surgery
This Phase 2 study tests two different medicines given after breast surgery to reduce the risk of cancer coming back. It is only for people with early-stage HER2-positive breast cancer with limited or no lymph node spread.
San Francisco, CaliforniaAges 18 years+ - NCT04899908RecruitingPhase 2
Brain radiation with or without gadolinium nanoparticles for brain metastases
This trial tests whether adding tiny gadolinium-containing nanoparticles to standard brain radiation can better control brain metastases from certain cancers. It is for people with tumors that have grown after immunotherapy, are from certain cancers (like melanoma, GI, or HER2+ breast), are cystic, are large, or have come back after prior radiation.
Boston, MassachusettsAges 18 years+ - NCT04802759RecruitingPhase 1/Phase 2
Testing drug combinations for recurrent or advanced ER-positive breast cancer
This early-phase trial tests several combinations of cancer medicines to slow or control ER-positive breast cancer that has returned or progressed. It also checks safety and whether tumor or blood biomarkers can help match the right treatment to the right person.
Duarte, CaliforniaAges 18 years+ - NCT04638725Recruiting
Genetics study to find why HER2 breast cancer treatment varies
This study looks at genetic factors to understand why some people’s HER2-positive breast cancer responds better—or has more side effects—after treatment. Your info and possible past treatment history may help researchers improve how HER2 treatment is chosen and managed.
StrasbourgAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Studying a new drug for cancers with a specific TP53 change
This trial tests a new drug (rezatapopt) for people with advanced cancers that have a specific change in the TP53 gene, called Y220C. The drug is designed to target this change and may slow or stop cancer growth. Some participants may also receive an immunotherapy drug called pembrolizumab (Keytruda).
Irvine, CaliforniaAges 12 years+ - NCT04517838Recruiting
Testing immune responses to anti-HER2 breast cancer treatments
This study looks at how your immune system reacts to anti-HER2 treatments in people with HER2-positive breast cancer. It may help doctors understand who responds best by studying immune signals in blood (and sometimes tissue) during or after treatment.
Jacksonville, FloridaAges 18 years+ - NCT04332588RecruitingPhase 1
Testing PET/MRI monitoring for HER2-positive breast cancer before surgery
This early-phase study looks at how well PET/MRI scans can monitor treatment response in people with HER2-positive breast cancer before surgery. You may be asked to undergo specific scans during “neoadjuvant” therapy (treatment given before the main operation).
Birmingham, AlabamaAges 18 years+ - NCT01042379RecruitingPhase 2
Adaptive drug trial for newly diagnosed breast cancer
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
Birmingham, AlabamaAges 18 years+ - NCT07520760RecruitingPhase 2
Eribulin Plus Anlotinib for HER2-Negative Breast Cancer
This trial tests a combination of two cancer drugs (eribulin and anlotinib) for women whose breast cancer has spread and stopped responding to previous treatments, particularly antibody-drug conjugates. The study aims to see if this combination can help slow or shrink the cancer.
GuangzhouAges 18 years+ - NCT07066917Recruiting
Breast cancer treatment response study
This study looks at how well newer treatments work for advanced or metastatic breast cancer and why some people respond better than others. It is for anyone with HR-positive, HER2-positive/low, or triple-negative breast cancer who has started at least one treatment cycle.
AthensAges 18 years+ - NCT07049133Recruiting
Tracking side effects of T-DXd for advanced breast cancer
This study looks at people with advanced breast cancer who will receive a drug called T-DXd. Researchers want to understand the side effects of this treatment by analyzing blood samples.
MilanAges 18 years+ - NCT07007169RecruitingPhase 2
Mediterranean diet study for early breast cancer
This trial tests whether eating a Mediterranean-style diet (rich in vegetables, fruits, whole grains, and healthy fats) can help improve outcomes for women with early breast cancer who are receiving chemotherapy. You will be asked to follow this diet and keep a food diary using an online tool.
Sønderborg, Southern DenmarkAges 18 years+ - NCT06259162Recruiting
LAG3 study in triple-negative breast cancer
This trial is studying a protein called LAG3 in triple-negative breast cancer. It is for people who will receive chemotherapy before surgery to see if LAG3 levels affect how well the treatment works.
SeoulAges Any age - NCT07264985Recruiting
Gut bacteria and diarrhea in breast cancer patients on pyrotinib
This study looks at how gut bacteria relate to diarrhea in breast cancer patients who are taking a drug called pyrotinib. By understanding this link, doctors hope to better manage side effects in the future.
Wuhan, HubeiAges 18–75 - NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99 - NCT07658170Recruiting
Fat graft with platelet-rich fibrin for breast reconstruction after lumpectomy
This trial tests using a patient's own fat plus a special blood product (platelet-rich fibrin) to rebuild the breast right after a lumpectomy for breast cancer. It may help improve healing and appearance for women with early-stage, hormone-sensitive breast cancer.
Saint PetersburgAges 18–69
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2-positive breast cancer?
- Yes. Clin2 currently lists 243 recruiting her2-positive breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2-positive breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2-positive breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- HER2-positive Metastatic Breast Cancer
- HER2-positive Advanced Breast Cancer
- HR-positive, HER2-negative Advanced Breast Cancer
- HER2-positive Early Breast Cancer
- HR Positive/HER2 Low Breast Cancer
- Hormone Receptor Positive / HER2-negative Breast Cancer
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.